Abstract
Remitting seronegative symmetrical synovitis and pitting edema (RS3PE) is an uncommon condition that is characterized as an acute polysynovitis associated with pitting edema that tends to affect individuals who are over 50 years of age. This condition was first described by McCarty et al. in 1985 and although now usually thought of as a separate entity was originally thought to represent a subset of late onset rheumatoid arthritis (LORA). The controversy over the last 30 years as to whether RS3PE is a separate entity or forms a part of a clinical spectrum that includes LORA and polymyalgia rheumatica (PMR) is due to the similarities in clinical and demographic characteristics that are shared by these conditions. Additionally, RS3PE is also considered a paraneoplastic condition as it is often associated with malignancy. In this chapter, we will discuss the epidemiological and clinical characteristics of RS3PE, associated conditions including malignancy, diagnosis and management, as well as current data on mechanism of disease pathogenesis including areas of ongoing research and future directions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
McCarty DJ, et al. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA. 1985;254(19):2763–7.
Okumura T, et al. The rate of polymyalgia rheumatica (PMR) and remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in a clinic where primary care physicians are working in Japan. Rheumatol Int. 2012;32(6):1695–9.
Karmacharya P, et al. RS3PE revisited: a systematic review and meta-analysis of 331 cases. Clin Exp Rheumatol. 2016;34(3):404–15.
Bucaloiu ID, Olenginski TP, Harrington TM. Remitting seronegative symmetrical synovitis with pitting edema syndrome in a rural tertiary care practice: a retrospective analysis. Mayo Clin Proc. 2007;82(12):1510–5.
Olivo D, et al. Benign edematous polysynovitis in the elderly (RS3PE syndrome). Clin Exp Rheumatol. 1994;12(6):669–73.
Olivieri I, Salvarani C, Cantini F. RS3PE syndrome: an overview. Clin Exp Rheumatol. 2000;18(4 Suppl 20):S53–5.
Oide T, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in Nagano, Japan: clinical, radiological, and cytokine studies of 13 patients. Clin Exp Rheumatol. 2004;22(1):91–8.
Li H, Altman RD, Yao Q. RS3PE: clinical and research development. Curr Rheumatol Rep. 2015;17(8):49.
Ohe M. A case of paraneoplastic syndrome. Soochunhyang Med Sci. 2014;20(2):91–5.
Tabeya T, et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2016;26(2):281–5.
Sayarlioglu M. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome and malignancy. Eur J Gen Med. 2004;1(2):3–5.
Russell EB. Remitting seronegative symmetrical synovitis with pitting edema syndrome: followup for neoplasia. J Rheumatol. 2005;32(9):1760–1.
Chen Y, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome: a case report. J Clin Gerontol Geriatr. 2011;2(1):27–9.
Gisserot O, et al. RS3PE revealing recurrent non-Hodgkin’s lymphoma. Joint Bone Spine. 2004;71(5):424–6.
Origuchi T, et al. Clinical outcomes in the first year of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome. Mod Rheumatol. 2017;27(1):150–4.
Emamifar A, et al. Association of remitting seronegative symmetrical synovitis with pitting edema, polymyalgia rheumatica, and adenocarcinoma of the prostate. Am J Case Rep. 2016;17:60–4.
Ferrao C, et al. Lucky to meet RS3PE. BMJ Case Rep. 2013;2013.
Alten R, Maleitzke T. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. Ann Med. 2013;45(4):357–63.
Schaeverbeke T, et al. Remitting seronegative symmetrical synovitis with pitting oedema: disease or syndrome? Ann Rheum Dis. 1995;54(8):681–4.
Berthier S, Toussirot E, Wendling D. Acute benign edematous polyarthritis in the elderly (or RA3PE syndrome). Clinical course apropos of 13 cases. Presse Med. 1998;27(34):1718–22.
Takeda K, et al. Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE syndrome) showing dermatomyositis-like eruption. J Dermatol. 2010;37(1):102–6.
Paira S, et al. Remitting seronegative symmetrical synovitis with pitting oedema: a study of 12 cases. Clin Rheumatol. 2002;21(2):146–9.
Pittau E, et al. Systemic lupus erythematosus with pitting oedema of the distal lower limbs. Br J Rheumatol. 1998;37(1):104–5.
Gunaydin I, et al. Lower limb pitting edema in systemic lupus erythematosus. Rheumatol Int. 1999;18(4):159–60.
Alpigiani MG, et al. Remitting symmetrical pitting edema of hands and feet at onset of pediatric systemic lupus erythematosus: a case report. Clin Exp Rheumatol. 2008;26(6):1166.
Hegazi MO, et al. Synovitis with pitting edema as the presenting manifestation of systemic lupus erythematosus. Lupus. 2014;23(10):1069–72.
Koeger AC, Karmochkine M, Chaibi P. RS3PE syndrome associated with advanced ankylosing spondylitis. J Rheumatol. 1995;22(2):375–6.
Salvarani C, Gabriel S, Hunder GG. Distal extremity swelling with pitting edema in polymyalgia rheumatica. Report on nineteen cases. Arthritis Rheum. 1996;39(1):73–80.
Diez-Porres L, et al. Remitting seronegative symmetrical synovitis with pitting oedema as the first manifestation of psoriatic arthropathy. Rheumatology (Oxford). 2002;41(11):1333–5.
Palazzi C, et al. Symmetrical pitting edema resembling RS3PE in gout. Clin Rheumatol. 2003;22(6):506–7.
Sugisaki K, Hirose T. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome following spontaneous rupture of a gouty tophus. Mod Rheumatol. 2008;18(6):630–3.
Hakozaki M, et al. Remitting seronegative symmetrical synovitis with pitting edema syndrome caused by crystal-induced arthritis of the wrist: a case report. Med Princ Pract. 2013;22(3):307–10.
Magy N, et al. Amyloid arthropathy revealed by RS3PE syndrome. Joint Bone Spine. 2000;67(5):475–7.
Moran Blanco A, et al. RS3PE syndrome associated to AL-amyloidosis and multiple myeloma, with intestinal pseudo-obstruction. Med Clin (Barc). 2003;120(2):79.
Matsuda M, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23(3):246–8.
Oyama K, et al. Remitting seronegative symmetrical synovitis with pitting edema syndrome in individuals with type 2 diabetes mellitus or impaired glucose tolerance. Diabetes Res Clin Pract. 2015;110(1):e5–8.
Cantini F, Salvarani C, Olivieri I. Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema. Clin Exp Rheumatol. 1999;17(6):741–4.
Salam A, Henry R, Sheeran T. Acute onset polyarthritis in older people: is it RS3PE syndrome? Cases J. 2008;1(1):132.
Salvarani C, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum. 1998;41(7):1221–6.
Schaeverbeke T, et al. Is remitting seronegative symmetrical synovitis with pitting oedema (RS3PE syndrome) associated with HLA-A2? Br J Rheumatol. 1995;34(9):889–90.
Matsuda M, et al. Remitting seronegative symmetrical synovitis with pitting oedema/polymyalgia rheumatica after infection with mycoplasma pneumoniae. Ann Rheum Dis. 2005;64(12):1797–8.
Drago F, et al. Remitting seronegative symmetrical synovitis with pitting edema associated with parvovirus B19 infection: two new cases and review of the comorbidities. Int J Dermatol. 2015;54(10):e389–93.
Perandones CE, Colmegna I, Arana RM. Parvovirus B19: another agent associated with remitting seronegative symmetrical synovitis with pitting edema. J Rheumatol. 2005;32(2):389–90.
Torres A, et al. Remitting seronegative symmetrical synovitis with pitting edema associated with subcutaneous Streptobacillus moniliformis abscess. J Rheumatol. 2001;28(7):1696–8.
Nicolas-Sanchez FJ, et al. RS3PE associated with tuberculosis. An Med Interna. 2007;24(10):494–6.
Helling CA, et al. Remitting seronegative symmetrical synovitis with pitting edema in leprosy. Clin Rheumatol. 2006;25(1):95–7.
Mouly S, Berenbaum F, Kaplan G. Remitting seronegative symmetrical synovitis with pitting edema following intravesical bacillus Calmette-Guerin instillation. J Rheumatol. 2001;28(7):1699–701.
Mainali NR, et al. Novel development of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome due to insulin therapy. Am J Case Rep. 2014;15:119–22.
Smyth D, et al. Remitting seronegative symmetrical synovitis with pitting oedema associated with rifampicin. Ir J Med Sci. 2011;180(2):585–6.
Yamauchi K, et al. RS3PE in association with dipeptidyl peptidase-4 inhibitor: report of two cases. Diabetes Care. 2012;35(2):e7.
Kimura M, et al. Clinical characteristics of patients with remitting seronegative symmetrical synovitis with pitting edema compared to patients with pure polymyalgia rheumatica. J Rheumatol. 2012;39(1):148–53.
Origuchi T, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22(4):584–8.
Sibilia J, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE): a form of paraneoplastic polyarthritis? J Rheumatol. 1999;26(1):115–20.
Fietta P, Manganelli P. Sjogren’s syndrome presenting as remitting seronegative symmetric synovitis with pitting edema (RS3PE): comment of the article by Choi et al. J Korean Med Sci. 2003;18(6):921.
Colmegna I, Alberts-Grill N. Parvovirus B19: its role in chronic arthritis. Rheum Dis Clin N Am. 2009;35(1):95–110.
El Mahou S, et al. Remitting seronegative symmetrical synovitis pitting oedema after BCG instillation. Clin Rheumatol. 2006;25(4):566–7.
Buchs N, Chevrel G, Miossec P. Bacillus Calmette-Guerin induced aseptic arthritis: an experimental model of reactive arthritis. J Rheumatol. 1998;25(9):1662–5.
Hughes RA, Allard SA, Maini RN. Arthritis associated with adjuvant mycobacterial treatment for carcinoma of the bladder. Ann Rheum Dis. 1989;48(5):432–4.
Klauser A, et al. Remitting seronegative symmetrical synovitis with pitting edema of the hands: ultrasound, color doppler ultrasound, and magnetic resonance imaging findings. Arthritis Rheum. 2005;53(2):226–33.
Jennbacken K, et al. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate. 2005;65(2):110–6.
Tanaka T, et al. Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Rheumatology (Oxford). 2010;49(4):824–6.
Lally L, et al. Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol. 2016;68(10):2550–4.
Mehta P, et al. Steroid-resistant remitting seronegative symmetrical synovitis with pitting oedema associated with gout treated with etanercept. Rheumatology (Oxford). 2014;53(10):1908–10.
Uddhammar A, et al. Cytokines and adhesion molecules in patients with polymyalgia rheumatica. Br J Rheumatol. 1998;37(7):766–9.
van der Geest KS, et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology (Oxford). 2015;54(8):1397–402.
Nakahara H, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003;48(6):1521–9.
Fuchs S, et al. Differential induction and regulation of matrix metalloproteinases in osteoarthritic tissue and fluid synovial fibroblasts. Osteoarthr Cartil. 2004;12(5):409–18.
Matsunaga T, et al. Myelodysplastic syndrome precedes the onset of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome. Tohoku J Exp Med. 2015;235(1):47–52.
Watanabe O, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in crow-Fukase (POEMS) syndrome. Muscle Nerve. 1998;21(11):1390–7.
Mittal K, Ebos J, Rini B. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. Semin Oncol. 2014;41(2):235–51.
Arima K, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653–5.
Ribbens C, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis. 2002;61(2):161–6.
Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 2004;23(1–2):101–17.
Yeh YC, et al. Elevated serum matrix metalloproteinase-3 and -7 in H. pylori-related gastric cancer can be biomarkers correlating with a poor survival. Dig Dis Sci. 2010;55(6):1649–57.
Yanai H, Yoshida H, Tada N. Clinical, radiological, and biochemical characteristics in patients with diseases mimicking polymyalgia rheumatica. Clin Interv Aging. 2009;4:391–5.
Shimojima Y, et al. Analysis of peripheral blood lymphocytes using flow cytometry in polymyalgia rheumatica, RS3PE and early rheumatoid arthritis. Clin Exp Rheumatol. 2008;26(6):1079–82.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Schorpion, A., Raveendran, R., Shahane, A., Kwan, M., Rivadeneira, A.C. (2019). Remitting Seronegative Symmetrical Synovitis and Pitting Edema. In: Tarrant, T. (eds) Rare Rheumatic Diseases of Immunologic Dysregulation. Rare Rheumatic Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-99139-9_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-99139-9_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-99138-2
Online ISBN: 978-3-319-99139-9
eBook Packages: MedicineMedicine (R0)